白芍总苷胶囊联合地氯雷他定治疗儿童单纯型过敏性紫癜的临床效果及可行性分析

Clinical effect and feasibility analysis of total glucoside paeoniae capsule combined with desloratadine in the treatment of children with simplex allergic purpura

目的:分析白芍总苷胶囊联合地氯雷他定治疗儿童单纯型过敏性紫癜的临床效果及可行性。方法:2018年1月-2020年1月收治儿童单纯型过敏性紫癜患者186例,随机分为两组,各93例。对照组给予地氯雷他定治疗,试验组在地氯雷他定基础上联合白芍总苷胶囊治疗,比较两组患者临床疗效、免疫功能指标水平和炎性因子水平。结果:试验组治疗总有效率高于对照组,差异有统计学意义(P<0.05);试验组治疗后Ig A水平低于对照组,IgM及IgG水平均高于对照组,差异有统计学意义(P<0.05);试验组治疗后白介素-4(IL-4)、白介素-6(IL-6)、白介素-8(IL-8)均低于对照组,差异有统计学意义(P<0.05)。结论:白芍总苷胶囊联合地氯雷他定治疗儿童单纯型过敏性紫癜,能够改善患儿免疫功能,抑制炎性反应,利于患儿病情恢复,治疗方案可行。

Objective:To analyze the clinical effect and feasibility of total glucoside paeoniae capsule combined with desloratadine in the treatment of children with simplex allergic purpura.Methods:From January 2018 to January 2020,186 children with simplistic allergic purpura were selected and randomly divided into two groups with 93 cases in each group.The control group was treated with desloratadine.The experimental group was treated with desloratadine combined with total glucosides paeoniae capsule.Clinical efficacy,immune function indexes and inflammatory factors were compared between the two groups.Results:The total effective rate of the experimental group was higher than the control group,with the difference was statistically significant(P<0.05).After treatment,the level of Ig A in the experimental group was lower than the control group,and the levels of Ig M and Ig G in the experimental group were higher than the control group,with the differences were statistically significant(P<0.05).After treatment,the levels of IL-4,IL-6 and IL-8 in the experimental group were lower than the control group,with the differences were statistically significant(P<0.05).Conclusion:Total glucoside paeoniae capsule combined with desloratadine in the treatment of children with simplex allergic purpura can improve the immune function,inhibit inflammatory response,and benefit the recovery of children’s condition,and the treatment scheme is feasible.